SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
777 W 41 St St, Suite 401, Miami Beach, Florida
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Big Cypress Acquisition Corp. (to 10/22/2021)
Latest financial report
Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 300 % +113%
Debt-to-equity 51 % -23.6%
Return On Equity -110 % -25%
Return On Assets -72.8 % -38.1%
Operating Margin -1.62 K % -592%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.23 M shares -82.4%
Common Stock, Shares, Outstanding 9.23 M shares -81.7%
Entity Public Float 30.7 M USD -6.22%
Common Stock, Value, Issued 929 USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 9.24 M shares +83.4%
Weighted Average Number of Shares Outstanding, Diluted 9.24 M shares +83.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5 K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.6 M USD -79.5%
Research and Development Expense 20.1 M USD -27.2%
General and Administrative Expense 24.5 M USD +67.6%
Operating Income (Loss) -42.1 M USD -42%
Nonoperating Income (Expense) 2.2 M USD -10.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.9 M USD -46.9%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -39.9 M USD -47.2%
Earnings Per Share, Basic -6.72 USD/shares -16.1%
Earnings Per Share, Diluted -0.54 USD/shares +63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14 M USD +7.46%
Cash, Cash Equivalents, and Short-term Investments 15 M USD -62%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 47 M USD +212%
Property, Plant and Equipment, Net 17.9 M USD -20%
Operating Lease, Right-of-Use Asset 1.08 M USD +12.5%
Assets 71.4 M USD +67.3%
Accounts Payable, Current 1.24 M USD -14.2%
Employee-related Liabilities, Current 1.92 M USD
Liabilities, Current 8.3 M USD -39.2%
Operating Lease, Liability, Noncurrent 555 K USD +144%
Liabilities 18.5 M USD +1.53%
Accumulated Other Comprehensive Income (Loss), Net of Tax -63.4 K USD
Retained Earnings (Accumulated Deficit) -95.1 M USD -72.2%
Stockholders' Equity Attributable to Parent 52.8 M USD +116%
Liabilities and Equity 71.4 M USD +67.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8 M USD -569%
Net Cash Provided by (Used in) Financing Activities -394 K USD -9.63%
Net Cash Provided by (Used in) Investing Activities -31.4 M USD -147126%
Common Stock, Shares Authorized 800 M shares +63.3%
Common Stock, Shares, Issued 9.28 M shares -81.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.5 M USD -2041%
Interest Paid, Excluding Capitalized Interest, Operating Activities 66.2 K USD -15.5%
Deferred Tax Assets, Valuation Allowance 19.2 M USD +55.9%
Deferred Tax Assets, Gross 22.1 M USD +39.5%
Operating Lease, Liability 1.1 M USD +47.2%
Payments to Acquire Property, Plant, and Equipment 129 K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.12 M USD +30.4%
Lessee, Operating Lease, Liability, to be Paid 1.19 M USD +52.9%
Property, Plant and Equipment, Gross 29.8 M USD +0.77%
Operating Lease, Liability, Current 543 K USD +4.79%
Lessee, Operating Lease, Liability, to be Paid, Year Two 310 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 372 K USD +0.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +32.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 93.7 K USD +182%
Lessee, Operating Lease, Liability, to be Paid, Year Three 310 K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.3 M USD +84.2%
Preferred Stock, Shares Issued 42.2 K shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 713 K USD -29.2%
Additional Paid in Capital 153 M USD +80.3%
Preferred Stock, Shares Outstanding 42.2 K shares
Depreciation, Depletion and Amortization 4.72 M USD +37.5%
Deferred Tax Assets, Net of Valuation Allowance 2.86 M USD -18.2%
Share-based Payment Arrangement, Expense 2.44 M USD +2.48%
Interest Expense 299 K USD -7.04%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%